Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
Yung Chan, Bik Sai Bessie Tong, Pui Yan Ngan, Chi Sum Au Apex Dermatology Institute, Kowloon, Hong KongCorrespondence: Yung Chan Room 1103-06, 11/F Hong Kong Pacific Centre, 28 Hankow Road, Tsim Sha Tsui, Kowloon, Hong KongTel + 852 3703 3580Fax + 852 3702 0018Email info@apexdermhk.comBackground: In...
Guardado en:
Autores principales: | Chan Y, Tong BSB, Ngan PY, Au CS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f2d0e28fac9544468770dc5222741b78 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton P, et al.
Publicado: (2021) -
Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou C, et al.
Publicado: (2018) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021)